Phase II Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 26 May 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 27 Mar 2018 Planned End Date changed from 1 Aug 2024 to 14 Dec 2023.
- 27 Mar 2018 Planned primary completion date changed from 1 Aug 2023 to 14 Dec 2020.
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.